Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of Niemann-Pick disease type C in the United States – Yahoo Finance

Check back at 8:30 a.m. ET for results

Orphazyme A/S
Investor
news
No. 02/2022
www.orphazyme.com
Company Registration No. 32266355

Orphazyme has made progress towards resubmission of the NDA for arimoclomol to the FDA and plans to request a Type C Meeting in Q2 2022
Subject to these discussions, the Company aims to resubmit the NDA during H2 2022
Copenhagen, Denmark, February 11, 2022 Orphazyme A/S (ORPHA.CO; ORPH) (“Orphazyme” or the “Company”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today provides an update on the process and anticipated timelines for resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational product candidate, arimoclomol, for the treatment of Niemann-Pick disease type C (NPC).
In line with recommendations from the FDA during a Type A Meeting held in October 2021, the Company intends to request a Type C Meeting to discuss the additional data, information, and analyses addressing certain topics in the Complete Response Letter (CRL) to align on a path to resubmission for arimoclomol in NPC with the FDA. The Company expects to request the Type C Meeting in Q2 2022. Subject to these discussions, the Company aims to resubmit the NDA during H2 2022.
Anders Vadsholt, Chief Financial Officer of Orphazyme said, “Requesting a Type C Meeting is the next step in establishing a potential path to resubmission of our NDA to the FDA. NPC is a rare neurodegenerative disease for which there are no approved treatments in the United States, and we look forward to continuing our interactions with the Agency as we seek to gain approval of arimoclomol in the United States for this devastating disease.”
The EU Marketing Authorisation Application (MAA) for arimoclomol for the treatment of NPC was filed with the European Medicines Agency (EMA) in November 2020. As previously communicated, an opinion from the Committee for Medicinal Products for Human Use (CHMP) on this application is expected in Q1 2022.
Christophe Bourdon, Chief Executive Officer of Orphazyme said, “Our team has been working at pace and we are looking forward to be interacting with an adhoc expert group in the coming weeks for the European submission.


For additional information, please contact
Orphazyme A/S
Anders Vadsholt, Chief Financial Officer +45 2898 9055


About Orphazyme A/S
Orphazyme is a late-stage biopharmaceutical company developing arimoclomol for Niemann-Pick disease type C (NPC). Orphazyme is headquartered in Denmark and has operations in the U.S. and Switzerland. ADSs representing Orphazyme’s shares are listed on Nasdaq U.S. (ORPH) and its shares are listed on Nasdaq Copenhagen (ORPHA).
About arimoclomol
Arimoclomol is an investigational drug candidate that amplifies the production of heat shock proteins (HSPs). HSPs can rescue defective misfolded proteins, clear protein aggregates, and improve the function of lysosomes. Arimoclomol is administered orally, and has now been studied in 10 Phase 1, four Phase 2, and three pivotal Phase 2/3 trials. Arimoclomol has received Orphan Drug Designation (ODD) for NPC in the US and EU. Arimoclomol has received Fast-Track Designation (FTD), Breakthrough Therapy Designation (BTD), and Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for NPC. On June 17, 2021, Orphazyme received a Complete Response Letter from the FDA regarding its New Drug Application for arimoclomol for the treatment of NPC. A marketing authorization application (MAA) for arimoclomol in NPC has been filed with the European Medicines Agency and is under review.
Forward-looking statement
This company announcement may contain certain forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995 and otherwise, including the U.S. and EU regulatory processes for the potential approval of arimoclomol and the resubmission of the NDA to the FDA. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements, including the risks and uncertainties that are described in the Risk Factors section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission (SEC) on March 2, 2021, the Company’s Report on Form 6-K filed with the SEC on June 11, 2021, and other filings Orphazyme makes with the SEC from time to time. These documents are available on the “Investors & Media” section of Orphazyme’s website at www.orphazyme.com. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
Attachment
02-2022 Orphazyme provides update for planned NDA resubmission for arimoclomol for the treatment of NPC in the US

PLTR stock fell as fourth quarter earnings missed estimates while March quarter revenue guidance edged by expectations.
Whether you realize it or not, stock market corrections, and even crashes, are an inevitable part of the investing cycle. According to a select group of analysts and investment banks, the latest correction could yield massive upside for a trio of supercharged growth stocks. If Wall Street's high-water price targets come to fruition, these fast-paced companies could rocket higher by 126% to as much as 248% over the next 12 months.
2022 has started out with a marked increase in market volatility, accompanied by a sharp reversal of last year’s bullish trend. The sudden correction, and the shift to a more downbeat investor sentiment, are generally attributed to a series of increased risk factors. On the international front, these tensions include geopolitical tensions on the Russia-Ukraine border and around China’s belligerence. Domestically, factors impacting the markets include the inflation that is both high and rising; a
Yahoo Finance's Dan Howley breaks down Nvidia's quarterly earnings report.
The stock market appears to be making a transition in these first few months of 2022, from last year’s bullish trend to a slower pace of growth this year. Headwinds are mounting – the pandemic is stubbornly persistent, inflation is high and trending higher, the Fed is getting set to raise interest rates in response, the list goes on – and so it’s natural for retail investors and experts alike to go looking for investing advice. And one source of advice is the circle of market gurus, the hedge fu
Since hitting an all-time high of $308.53 last July, shares of PayPal Holdings (NASDAQ: PYPL) have fallen dramatically, losing more than 60% of their value at Wednesday's prices. The company's revenue growth has decelerated, as the pandemic boost seems to be fading away. Investors are now questioning the payments giant's future.
Mark Zuckerberg wants to completely cut off all ties between Facebook and the controversies that have marked the daily life of the social media giant over the past five years. This attempt at purification began last October when he changed Facebook's name to Meta and imposed the concept of metaverse in conversations and business circles. Zuckerberg now wants Facebook employees to be called 'Metamates'.
RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here. The RiverPark Large Growth Fund (the “Fund”) returned -3.23% for the third quarter of 2021, while its benchmarks, the S&P 500 Total Return Index (“S&P”) advanced 0.58%, the Russell […]
Discover the best Vanguard funds via the Morningstar rating system. Learn more about three funds that have five-star ratings from Morningstar here.
QuantumScape reported fourth-quarter results Wednesday evening. The pre-sales company said it met all of its 2021 goals.
Palantir Technologies forecast current-quarter sales above estimates on Thursday, after a steady flow of government contracts and a growing commercial portfolio boosted the data analytics software firm's fourth-quarter revenue. Known for its work with the U.S. Army, the Central Intelligence Agency and other government bodies, Palantir's next leg of growth is widely expected to come from commercial contracts with large businesses.
Yahoo Finance's Jared Blikre examines the after-hour action surrounding tech manufacturer Cisco Systems after beating earnings and revenue estimates.
Futures fell with Russia's Ukraine comments in focus. Investors don't have a trading edge while the market rally is rangebound.
The race is on to add dividends to stock portfolios. But investors are still being picky in the S&P 500 — and know what they're looking for.
The Fed is getting ready to make its move. Prepare your portfolio by buying stocks that benefit from higher rates. Protect it further by using options.
Walmart defied supply chain disruptions, wage increases in input costs with stronger-than-expected holiday quarter earnings and a modest dividend boost.
In this post, we will take a look at ten growth stocks from the semiconductor industry. If you want to skip our introduction and jump straight to the top five stocks, then head on over to 5 Semiconductor Stocks With Growth Potential. The semiconductor industry is one of the hottest topics in the technology sector […]
Yahoo FInance's Rachelle Akuffo and Jared Blikre examine DoorDash's growth in users and revenue, in addition to Fisker's earnings beat.
Nvidia reported its Q4 earnings on Wednesday, beating analysts' estimates.
(Bloomberg) — Shopify Inc. plunged 17% in Toronto, the most ever, after giving a weaker outlook for growth this year, as online spending resets and consumers face higher inflation. Most Read from BloombergStocks Edge Higher With Fed Hiking Bets Steady: Markets WrapHong Kong to Mass Test Whole City for Covid With Beijing’s HelpJho Low’s Wild Nights on Display: $250,000 for DiCaprio, FoxFed Eyes Rate Hike Soon and Faster Tightening Pace If NeededTrump's Accountants Just Quit. What Took So Long?“T

source

Leave a Comment

Your email address will not be published.

Shopping Cart